Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda.


Journal

The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019

Informations de publication

Date de publication:
Jan 2022
Historique:
pubmed: 2 11 2021
medline: 2 11 2021
entrez: 1 11 2021
Statut: ppublish

Résumé

The potential effects of SARS-CoV-2 and This was an exploratory prospective, cohort study of patients with COVID-19 who were admitted to hospital in Uganda. Patients of all ages with a PCR-confirmed diagnosis of SARS-CoV-2 infection who had provided informed consent or assent were consecutively enrolled from treatment centres in eight hospitals across the country and followed up until discharge or death. Clinical assessments and blood sampling were done at admission for all patients. Malaria diagnosis in all patients was done by rapid diagnostic tests, microscopy, and molecular methods. Previous Of 600 people with PCR-confirmed SARS-CoV-2 infection enrolled from April 15, to Oct 30, 2020, 597 (>99%) had complete information and were included in our analyses. The majority (502 [84%] of 597) were male individuals with a median age of 36 years (IQR 28-47). Overall prevalence of Although patients with COVID-19 with Malaria Consortium (USA).

Sections du résumé

BACKGROUND BACKGROUND
The potential effects of SARS-CoV-2 and
METHODS METHODS
This was an exploratory prospective, cohort study of patients with COVID-19 who were admitted to hospital in Uganda. Patients of all ages with a PCR-confirmed diagnosis of SARS-CoV-2 infection who had provided informed consent or assent were consecutively enrolled from treatment centres in eight hospitals across the country and followed up until discharge or death. Clinical assessments and blood sampling were done at admission for all patients. Malaria diagnosis in all patients was done by rapid diagnostic tests, microscopy, and molecular methods. Previous
FINDINGS RESULTS
Of 600 people with PCR-confirmed SARS-CoV-2 infection enrolled from April 15, to Oct 30, 2020, 597 (>99%) had complete information and were included in our analyses. The majority (502 [84%] of 597) were male individuals with a median age of 36 years (IQR 28-47). Overall prevalence of
INTERPRETATION CONCLUSIONS
Although patients with COVID-19 with
FUNDING BACKGROUND
Malaria Consortium (USA).

Identifiants

pubmed: 34723228
doi: 10.1016/S2666-5247(21)00240-8
pii: S2666-5247(21)00240-8
pmc: PMC8545833
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e62-e71

Informations de copyright

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Déclaration de conflit d'intérêts

HA and FN are members of the Mulago Hospital Research and Ethics but did not participate in decisions pertaining to this study. All other authors declare no competing interests.

Références

Expert Rev Anti Infect Ther. 2012 Nov;10(11):1343-56
pubmed: 23241191
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
Lancet Infect Dis. 2021 Nov;21(11):1568-1578
pubmed: 34146476
PLoS One. 2021 Apr 29;16(4):e0250330
pubmed: 33914789
Natl Sci Rev. 2020 Jun;7(6):1003-1011
pubmed: 34676126
Sci Rep. 2021 Mar 5;11(1):5322
pubmed: 33674708
Respir Res. 2020 Sep 22;21(1):245
pubmed: 32962703
JAMA. 2020 Nov 24;324(20):2100-2102
pubmed: 33044514
Clin Infect Dis. 2020 Jun 10;70(12):2544-2552
pubmed: 31402382
Malar J. 2017 Dec 29;16(1):499
pubmed: 29284469
J Infect Dis. 2012 Dec 1;206(11):1674-84
pubmed: 22984118
Nat Med. 2020 Sep;26(9):1411-1416
pubmed: 32770167
Am J Trop Med Hyg. 2020 Aug;103(2):572-577
pubmed: 32484155
Am J Trop Med Hyg. 2020 Dec;103(6):2419-2428
pubmed: 33009770
PLoS Med. 2015 Mar 03;12(3):e1001788
pubmed: 25734259
J Exp Med. 2005 Jan 3;201(1):19-25
pubmed: 15630134
PLoS One. 2020 Nov 3;15(11):e0241742
pubmed: 33141836
Trop Med Infect Dis. 2020 Jul 24;5(3):
pubmed: 32722014
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32912856
Clin Vaccine Immunol. 2015 May;22(5):477-83
pubmed: 25716232
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
EClinicalMedicine. 2020 Jul 31;26:100483
pubmed: 33089116
Pharmacol Res. 2020 Aug;158:104931
pubmed: 32446978
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4438-47
pubmed: 26216993
Wellcome Open Res. 2019 Feb 8;4:26
pubmed: 32518839
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089

Auteurs

Jane Achan (J)

Global Technical Team, Malaria Consortium, London, UK.

Asadu Serwanga (A)

Technical Department, Malaria Consortium, Kampala, Uganda.

Humphrey Wanzira (H)

Technical Department, Malaria Consortium, Kampala, Uganda.

Tonny Kyagulanyi (T)

Technical Department, Malaria Consortium, Kampala, Uganda.

Anthony Nuwa (A)

Technical Department, Malaria Consortium, Kampala, Uganda.

Godfrey Magumba (G)

Technical Department, Malaria Consortium, Kampala, Uganda.

Stephen Kusasira (S)

Directorate of Health, Ministry of Defense, Kampala, Uganda.

Isaac Sewanyana (I)

Central Public Health Laboratories, Ministry of Health, Kampala, Uganda.

Kevin Tetteh (K)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Chris Drakeley (C)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Fredrick Nakwagala (F)

Department of Medicine, Mulago Specialist Referral Hospital, Kampala, Uganda.

Helen Aanyu (H)

Department of Paediatrics and Child Health, Mulago Specialist Referral Hospital, Kampala, Uganda.

Jimmy Opigo (J)

National Malaria Control Division, Ministry of Health, Kampala, Uganda.

Prudence Hamade (P)

Global Technical Team, Malaria Consortium, London, UK.

Madeleine Marasciulo (M)

Global Technical Team, Malaria Consortium, Raleigh, NC, USA.

Byarugaba Baterana (B)

Department of Medicine, Mulago Specialist Referral Hospital, Kampala, Uganda.

James K Tibenderana (JK)

Global Technical Team, Malaria Consortium, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH